SCHEDULE: Strategic EP Discloses 5.1% Stake in Lixte Biotechnology

Strategic EP, LLC and Alexander Chase Deitch have filed a Schedule 13G disclosing a 5.1% beneficial ownership stake in Lixte Biotechnology Holdings, Inc.

Summary

• Strategic EP, LLC and Alexander Chase Deitch reported beneficial ownership of 774,902 shares of Lixte Biotechnology Holdings, Inc. common stock.
• The reported stake represents 5.1% of the company's outstanding common stock.
• The ownership calculation is based on 15,278,806 shares outstanding as of June 2, 2026.
• The reporting persons hold additional warrants for 545,521 shares, but these are currently restricted from exercise by a 4.99% ownership cap provision.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine regulatory disclosure of a passive investment stake.

Positives

• The acquisition of a 5.1% stake indicates significant investor interest in Lixte Biotechnology.
• The reporting persons have certified that the shares were not acquired for the purpose of changing or influencing control of the issuer.

Negatives

• The reporting persons are currently limited by a 4.99% ownership cap on warrant exercises, preventing immediate conversion of additional holdings.

Risks

• The investment is subject to the volatility inherent in biotechnology stocks.
• The 4.99% ownership cap on warrants limits the ability of the reporting persons to increase their stake through warrant exercise without further regulatory or corporate adjustments.

Future Outlook

The reporting persons have stated they do not intend to influence or change the control of the issuer, suggesting a passive investment stance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings in the biotechnology sector often signal institutional confidence in a company's clinical pipeline or valuation, though they are frequently passive in nature.

Comparison to Industry Standards

• The 5.1% threshold is a standard regulatory trigger for disclosure under the Securities Exchange Act of 1934.
• The use of a 4.99% ownership cap on warrants is a common protective measure in biotech financing to avoid triggering change-of-control provisions or complex regulatory filings.

Stakeholder Impact

• Shareholders may view the entry of a new 5% holder as a sign of institutional validation of the company's prospects.

Next Steps

• The reporting persons are required to file amendments to this Schedule 13G if there are material changes to their ownership percentage.

Key Dates

Keywords

Lixte Biotechnology, Schedule 13G, Strategic EP, Alexander Chase Deitch, Biotech, Institutional Ownership